Table 1.

Selected published results of SRS (2000–2015) for the treatment of nonfunctioning pituitary adenomas

Authors	Patients	Type	dose	Follow-up	Tumor	Late toxicity (%)
		of SRS	(Gy)	(months)	control (%)	visual	hypopituitarism
Feigl et al., 2002 [33]	61	GK	15a	55.2	94	NA	40
Sheehan et al., 2002 [58]	42	GK	16a	31.2	97.6	2.4	0
Wowra & Stummer, 2002 [59]	30	GK	16a	55	93.3 (93 at 5 years)	0	10
Petrovich et al., 2003 [60]	56	GK	15a	36	100	3	4
Losa et al., 2004 [61]	52	GK	16.6a	41	96.3 (88.2 at 5 years)	0	9.3
Muacevic et al., 2004 [62]	51	GK	16.5a	21.7	95	0	3.9
Picozzi et al., 2005 [63]	51	GK	16.5a	40.6	96.1	NA	NA
Iwai et al., 2005 [64]	34	GK	12.3a	59.8	87.1 (93 at 5 years)	0	6.5
Mingione et al., 2006 [65]	100	GK	18.5a	44.9	92.2	0	19.7
Voges et al., 2006 [66]	37	LINAC	13.4	56.6	100	1.4	12.3
Liscak et al., 2007 [67]	140	GK	20a	60	100	0	2
Pollock et al., 2008 [68]	62	GK	16a	64	96.8 (95 at 5 years)	0	27
Kobayashi et al., 2009 [69]	71	GK	14.1a	50.2	96.7	2.8	8.2
Hayashi et al., 2010 [70]	43	GK	18.2a	36	100	0	0
Gopalan et al., 2011 [71]	48	GK	18.4a	95	83.3	0	39
Iwata et al., 2011 [44]	100	CK	3×7/5×5	33	98	1	3
Park et al., 2011 [72]	125	GK	13a	62	90 (94 at 5 years)	0,8	24
Starke et al., 2012 [73]	140	GK	18a	50	89.6 (97 at 5 years)	0	30.3
Runge et al., 2012 [74]	61	LINAC	13	83	98	0	9.8
Wilson et al., 2012 [75]	51	LINAC	14	50	100	0	0
Sheehan et al., 2013 [76]	512	GK	16a	36	93.4 (95 at 5 years)	7.9	21
Lee et al., 2014 [77]	41	GK	12a	48	92.7 (85 at 10 years)	2.4	24.4
Bir et al., 2015 [78]	57	GK	15a	45.5	93 (90 % at 10 years)	0	8.8

SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed

^amarginal dose